Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy (AT-TARGET-IT)

Federico II University

Status: Enrolling

Conditions: Hypercholesterolemia

Treatments: Drug: Repatha (evolocumab); Praluent (alirocumab)

Study type: Observational

Funder types: Other

Identifiers

NCT05430828

264/20

Details and patient eligibility

About

Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients under PCSK9 inhibitor treatment.

Exclusion criteria

• Age < 18 years o > 80 years;
• Patients who refuse to participate and to sign informed consent.

Trial design

2,000 participants in 1 patient group

Group 1

Description:

Subjects with hyperlipidaemia under PCSK9 inhibitors treatment (Repatha/Praulent).

Treatment:

Drug: Repatha (evolocumab); Praluent (alirocumab)